A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human

Johannes D Veldhuis, T. J. Worgul, R. Monsaert, J. M. Hammond

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We investigated the participation by endogenous opioid peptides in the control of prolactin and gonadotropin secretion in 5 normal men and 6 normal women and in 4 men and 5 women with persisting hyperprolactinemia following transsphenoidal pituitary microsurgery for prolactinomas. Iv administration of the specific opiate-receptor antagonist, naloxone hydrochloride (0.2 mg/kg bolus), failed to affect serially sampled serum prolactin levels in normal male or female subjects. With prolactinemia patients, naloxone suppressed hyperprolactinemia to 37% and 32% of mean control values in 2 of 4 males, but in none of 6 females. When luteinizing hormone was serially sampled under the same conditions, 5 of 5 normal males (but no female, normal or abnormal) demonstrated a monophasic increase in serum LH concentrations after injection of the antagonist. The LH peak was 55% ± 4% above basal levels (p<0.01). In contrast to normal men, only one of 4 hyperprolactinemic male patients manifested a stimulatory response of LH to naloxone. Among all 20 subjects, none exhibited a change in FSH levels acutely after naloxone. These data suggest that: naloxone will not fulfill its postulated role as an ideal therapy for hyperprolactinemia and hypogonadotropism, at least in women; endogenous opioids may participate in the neuroendocrine regulation of LH secretion in the normal human; male-female differences may modify the role of endogenous opioids; and some male patients with hyperprolactinemia exhibit defective opioid-related neuroregulation of LH secretion.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalJournal of Endocrinological Investigation
Volume4
Issue number1
StatePublished - 1981
Externally publishedYes

Fingerprint

Luteinizing Hormone
Prolactin
Opioid Analgesics
Naloxone
Hyperprolactinemia
Prolactinoma
Opioid Peptides
Microsurgery
Opioid Receptors
Serum
Gonadotropins
Injections

ASJC Scopus subject areas

  • Endocrinology

Cite this

A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human. / Veldhuis, Johannes D; Worgul, T. J.; Monsaert, R.; Hammond, J. M.

In: Journal of Endocrinological Investigation, Vol. 4, No. 1, 1981, p. 31-36.

Research output: Contribution to journalArticle

Veldhuis, Johannes D ; Worgul, T. J. ; Monsaert, R. ; Hammond, J. M. / A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human. In: Journal of Endocrinological Investigation. 1981 ; Vol. 4, No. 1. pp. 31-36.
@article{1d89817b80354e8981f7178534cc93c0,
title = "A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human",
abstract = "We investigated the participation by endogenous opioid peptides in the control of prolactin and gonadotropin secretion in 5 normal men and 6 normal women and in 4 men and 5 women with persisting hyperprolactinemia following transsphenoidal pituitary microsurgery for prolactinomas. Iv administration of the specific opiate-receptor antagonist, naloxone hydrochloride (0.2 mg/kg bolus), failed to affect serially sampled serum prolactin levels in normal male or female subjects. With prolactinemia patients, naloxone suppressed hyperprolactinemia to 37{\%} and 32{\%} of mean control values in 2 of 4 males, but in none of 6 females. When luteinizing hormone was serially sampled under the same conditions, 5 of 5 normal males (but no female, normal or abnormal) demonstrated a monophasic increase in serum LH concentrations after injection of the antagonist. The LH peak was 55{\%} ± 4{\%} above basal levels (p<0.01). In contrast to normal men, only one of 4 hyperprolactinemic male patients manifested a stimulatory response of LH to naloxone. Among all 20 subjects, none exhibited a change in FSH levels acutely after naloxone. These data suggest that: naloxone will not fulfill its postulated role as an ideal therapy for hyperprolactinemia and hypogonadotropism, at least in women; endogenous opioids may participate in the neuroendocrine regulation of LH secretion in the normal human; male-female differences may modify the role of endogenous opioids; and some male patients with hyperprolactinemia exhibit defective opioid-related neuroregulation of LH secretion.",
author = "Veldhuis, {Johannes D} and Worgul, {T. J.} and R. Monsaert and Hammond, {J. M.}",
year = "1981",
language = "English (US)",
volume = "4",
pages = "31--36",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",
number = "1",

}

TY - JOUR

T1 - A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human

AU - Veldhuis, Johannes D

AU - Worgul, T. J.

AU - Monsaert, R.

AU - Hammond, J. M.

PY - 1981

Y1 - 1981

N2 - We investigated the participation by endogenous opioid peptides in the control of prolactin and gonadotropin secretion in 5 normal men and 6 normal women and in 4 men and 5 women with persisting hyperprolactinemia following transsphenoidal pituitary microsurgery for prolactinomas. Iv administration of the specific opiate-receptor antagonist, naloxone hydrochloride (0.2 mg/kg bolus), failed to affect serially sampled serum prolactin levels in normal male or female subjects. With prolactinemia patients, naloxone suppressed hyperprolactinemia to 37% and 32% of mean control values in 2 of 4 males, but in none of 6 females. When luteinizing hormone was serially sampled under the same conditions, 5 of 5 normal males (but no female, normal or abnormal) demonstrated a monophasic increase in serum LH concentrations after injection of the antagonist. The LH peak was 55% ± 4% above basal levels (p<0.01). In contrast to normal men, only one of 4 hyperprolactinemic male patients manifested a stimulatory response of LH to naloxone. Among all 20 subjects, none exhibited a change in FSH levels acutely after naloxone. These data suggest that: naloxone will not fulfill its postulated role as an ideal therapy for hyperprolactinemia and hypogonadotropism, at least in women; endogenous opioids may participate in the neuroendocrine regulation of LH secretion in the normal human; male-female differences may modify the role of endogenous opioids; and some male patients with hyperprolactinemia exhibit defective opioid-related neuroregulation of LH secretion.

AB - We investigated the participation by endogenous opioid peptides in the control of prolactin and gonadotropin secretion in 5 normal men and 6 normal women and in 4 men and 5 women with persisting hyperprolactinemia following transsphenoidal pituitary microsurgery for prolactinomas. Iv administration of the specific opiate-receptor antagonist, naloxone hydrochloride (0.2 mg/kg bolus), failed to affect serially sampled serum prolactin levels in normal male or female subjects. With prolactinemia patients, naloxone suppressed hyperprolactinemia to 37% and 32% of mean control values in 2 of 4 males, but in none of 6 females. When luteinizing hormone was serially sampled under the same conditions, 5 of 5 normal males (but no female, normal or abnormal) demonstrated a monophasic increase in serum LH concentrations after injection of the antagonist. The LH peak was 55% ± 4% above basal levels (p<0.01). In contrast to normal men, only one of 4 hyperprolactinemic male patients manifested a stimulatory response of LH to naloxone. Among all 20 subjects, none exhibited a change in FSH levels acutely after naloxone. These data suggest that: naloxone will not fulfill its postulated role as an ideal therapy for hyperprolactinemia and hypogonadotropism, at least in women; endogenous opioids may participate in the neuroendocrine regulation of LH secretion in the normal human; male-female differences may modify the role of endogenous opioids; and some male patients with hyperprolactinemia exhibit defective opioid-related neuroregulation of LH secretion.

UR - http://www.scopus.com/inward/record.url?scp=0019829922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019829922&partnerID=8YFLogxK

M3 - Article

C2 - 7240669

AN - SCOPUS:0019829922

VL - 4

SP - 31

EP - 36

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 1

ER -